BEGIN:VCALENDAR
VERSION:2.0 
PRODID:-/-/EN
BEGIN:VEVENT
SUMMARY:2025 Annual Scientific Meeting
UID:9
DESCRIPTION: After the success of our 2024 Annual Scientific Meeting in Manchester, we are excited to invite you to our 2025 meeting, which will be held ay Churchill College, Cambridge.Churchill College, part of the historic University of Cambridge, offers a distinguished and inspiring venue for our gathering. Cambridge itself is renowned for its beautiful architecture, rich academic heritage, and vibrant atmosphere, making it a perfect setting for our next meeting.Building on the achievements of Manchester, the 2025 meeting will continue to deliver a diverse and engaging programme that spans the breadth of hypertension research and care. As always, there will be a strong focus on oral presentations, insightful lectures, and opportunities for networking with colleagues and distinguished guests.The annual dinner will take place in Trinity Hall, a unique Cambridge venue, with further details to be announced soon. This promises to be a memorable evening and a highlight of the meeting.We look forward to welcoming you to Cambridge and sharing another exceptional event with you.For a PDF copy of the programme, please download HERE. \n\nOur SponsorsWe would like to thank all of our sponsors who have provided a sponsorship towards this independent programme. Our sponsors have had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for their own sponsored symposia.\n\nAbout AstraZenecaAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. The company is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,700 employees work in research and development, manufacturing, supply, sales, and marketing. We supply around 36 different medicines to the NHS. \nFor more information, please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK.  \n\n\n\nAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com/uk or www.boehringer-ingelheim.com/ireland.                                                           \n\n \n\n'44th Annual Scientific Meeting' has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 14 category 1 (external) CPD credits. (code: 152582)\n\nEthical MedTech - COMPLIANT \n\n
DTSTART:20250929T073000Z
DTEND:20250930T160000Z
LOCATION:Churchill College, Storey's Way, Cambridge CB3 0DS,
END:VEVENT
END:VCALENDAR